TABLE 4.
Immunohistochemical Staining for AIFM1, FTL, NNT, PRKDC, and TNIK in Amygdala Sections From a Convenience Sample of 12 Test Cases From the University of Kentucky AD Center Biobank
| Age | Sex | CDR (G) | Clin Dx | Antibody Staining Inclusion Body-Like Structures* |
Braak NFT Stage | Medial Temporal Lobe Neuropathology |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRKDC | FTL | AIFM1 | TNIK | NNT | Aβ | α-SN | TDP-43 | |||||
| 80 | F | 0 | NL | 0 | 1 | 0 | 0 | 0 | I | N | N | 0 |
| 77 | M | 0 | NL | 1 | 1 | 0 | 0 | 0 | I | N | N | +/− |
| 95 | F | 0 | NL | 1 | 0 | 0 | +/− | 0 | I | N | N | 0 |
| 84 | F | 0.5 | MCI | 2 | 1 | 2 | 2 | 0 | I | N | N | 2 |
| 91 | M | 0.5 | MCI | 1 | 1 | 1 | +/− | 0 | II | N | N | 0 |
| 91 | F | 0.5 | MCI | 2 | 0 | +/− | 0 | 1 | III | Y | N | 0 |
| 97 | M | 1 | PAD | +/− | 1 | 0 | +/− | 0 | II | N | N | 0 |
| 87 | F | 3 | PAD | 1 | 0 | +/− | 0 | 1 | II | Y | Y | 0 |
| 88 | F | 1 | PAD | 1 | 0 | +/− | +/− | 1 | II | N | N | 2 |
| 87 | F | 2 | PAD | 2 | 2 | 2 | 2 | 2 | III | Y | Y | 2 |
| 89 | F | 3 | PAD | 1 | 0 | +/− | +/− | 1 | IV | Y | N | 2 |
| 87 | F | 3 | PAD | 2 | 1 | 2 | 2 | 1 | VI | Y | Y | 2 |
CDR(G), global clinical dementia rating (0–3 scale); Clin Dx, final clinical diagnosis; PAD, final clinical diagnosis was probable Alzheimer disease; MCI, mild cognitive impairment; NL, cognitively intact.
*
Semiquantitative scale: 0 = no inclusions seen; +/− = equivocal; 1 = scattered immunoreactive inclusions, most or almost all <2 per high-power microscope field; 2 = common >2 inclusions per high-power field.